Cargando…

Novel Combination Therapies for the Treatment of Bladder Cancer

Bladder cancer is the ninth most frequently diagnosed cancer world-wide and ranks 13th in cancer-related deaths. Two tremendous breakthroughs in bladder cancer therapy over the last decades are the approval of immune checkpoint inhibitors(ICIs)and the fibroblast growth factor receptor tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Mei, Xiao, Di, Bu, Yizhi, Long, Jiahui, Yang, Xue, Lv, Shuhe, Yang, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873600/ https://www.ncbi.nlm.nih.gov/pubmed/33585182 http://dx.doi.org/10.3389/fonc.2020.539527

Ejemplares similares

Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019
por: Chu, Xuetong, et al.
Publicado: (2021)

Traditional Classification and Novel Subtyping Systems for Bladder Cancer
por: Zhu, Shaoming, et al.
Publicado: (2020)

Editorial: Novel Combination Therapies for the Treatment of Solid Cancers
por: Ayoub, Nehad M.
Publicado: (2021)

Novel application of metformin combined with targeted drugs on anticancer treatment
por: Deng, Jun, et al.
Publicado: (2018)

Identifying novel biomarkers associated with bladder cancer treatment outcomes
por: Castaneda, Peris R., et al.
Publicado: (2023)

Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
por: Peng, Mei, et al.
Publicado: (2019)

Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer
por: Huang, Haiming, et al.
Publicado: (2021)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
por: Wu, Jing, et al.
Publicado: (2022)

A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
por: Yang, Libo, et al.
Publicado: (2021)

Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma
por: You, Jia, et al.
Publicado: (2022)

Combination of C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio as a Novel Prognostic Index in Patients With Bladder Cancer After Radical Cystectomy
por: Wang, Yidi, et al.
Publicado: (2021)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Natural Phytochemicals in Bladder Cancer Prevention and Therapy
por: Xia, Yong, et al.
Publicado: (2021)

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis
por: Xiang, Peng, et al.
Publicado: (2021)

En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer
por: Yang, Yongjun, et al.
Publicado: (2021)

M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer
por: Zhu, Huili, et al.
Publicado: (2021)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer
por: Chen, Peng, et al.
Publicado: (2023)

Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab
por: Tao, Zhu-lei, et al.
Publicado: (2022)

The prognosis of bladder cancer is affected by fatty acid metabolism, inflammation, and hypoxia
por: Xiao, Yu, et al.
Publicado: (2022)

Efficacy and safety of photodynamic therapy for non–muscle-invasive bladder cancer: a systematic review and meta-analysis
por: Li, Haitao, et al.
Publicado: (2023)

Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis
por: Zang, Jingyu, et al.
Publicado: (2021)

Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis
por: Wang, Yejinpeng, et al.
Publicado: (2019)

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
por: Xu, Donghan, et al.
Publicado: (2023)

Insights Into Ferroptosis, a Novel Target for the Therapy of Cancer
por: Wang, Hong-Tao, et al.
Publicado: (2022)

The Roles of Glycans in Bladder Cancer
por: Jian, Yuli, et al.
Publicado: (2020)

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective
por: Yang, Yongjun, et al.
Publicado: (2023)

Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects
por: Guo, Bin, et al.
Publicado: (2023)

Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
por: Zhou, Xianghong, et al.
Publicado: (2020)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
por: Xu, Chaojie, et al.
Publicado: (2022)

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
por: Yang, Xiao, et al.
Publicado: (2022)

Role of NRP1 in Bladder Cancer Pathogenesis and Progression
por: Dong, Yang, et al.
Publicado: (2021)

Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer
por: Lou, Kecheng, et al.
Publicado: (2022)

Biological Roles and Clinical Significance of Exosome-Derived Noncoding RNAs in Bladder Cancer
por: Tong, Yonghua, et al.
Publicado: (2021)

Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study
por: Guan, Xu, et al.
Publicado: (2021)

Calreticulin as Cancer Treatment Adjuvant: Combination with Photodynamic Therapy and Photodynamic Therapy-Generated Vaccines
por: Korbelik, Mladen, et al.
Publicado: (2015)

Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer
por: Ayati, Mohsen, et al.
Publicado: (2017)

Impact of SOX2 function and regulation on therapy resistance in bladder cancer
por: Chen, Guodong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kvqsg1la1bepd57lgb52831ogf